Mubadala Strengthens UAE's Life Sciences with Key Acquisitions

Mubadala Investment Company PJSC, a sovereign wealth fund based in Abu Dhabi, has secured an 80% ownership stake in Global Medical Supply Chain (GMSC) and Al Ittihad Drug Store (IDS). This acquisition was made from GlobalOne Healthcare Holding (GHH), with GHH retaining a 20% interest. The deal significantly strengthens Mubadala's presence in the healthcare logistics and pharmaceutical distribution sectors, in line with the UAE’s strategic vision to build a robust life sciences infrastructure.

Founded in 2015, GMSC specializes in providing end-to-end supply chain services for medical products. These services include demand planning, procurement, logistics, inventory management, warehousing, and maintenance. GMSC supports over 200 medical facilities, including hospitals and clinics across the UAE. The company works with a dedicated team of medical supply chain professionals and sources a wide variety of products from nearly 400 suppliers, ensuring a dependable supply chain for healthcare providers.

IDS: A Key Player in Pharmaceutical Distribution

Established in 1987, IDS is one of the UAE’s foremost distributors of pharmaceutical and consumer healthcare products. With a portfolio of over 1,000 products from more than 40 leading suppliers, IDS services hospitals, pharmacies, and supermarkets throughout the UAE. The company offers a broad range of therapeutic categories, including anti-infectives, asthma treatments, diabetes care, and oncology products, making it a key player in the region's healthcare distribution network.

Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala's UAE Investments Platform, commented on the acquisition: “The expanding pharmaceutical market drives an increasing demand for specialized and efficient drug logistics solutions. By integrating GMSC and IDS into our portfolio, we are poised to create a vertically integrated life sciences sector in the UAE and enable its potential to encompass the entire value chain from logistics and distribution to specialized manufacturing.”

Low Ping, Group CEO Yas Holding commented: “This transaction continues Mubadala's strategic growth, following another significant acquisition by its new specialty pharmaceutical business, KELIX bio, which recently acquired a 100% stake in four pharma assets from GlobalOne Healthcare Holding’s (GHH), the healthcare division of Yas Holding. These concerted efforts underline Mubadala's commitment to strengthening the UAE's healthcare and pharmaceutical sectors as part of broader national ambitions for drug security and economic diversification.”

GHH: A Healthcare Investment Leader

GlobalOne Healthcare Holding LLC (GHH) is the healthcare division of Yas Holding LLC. GHH focuses on improving healthcare outcomes by investing in innovative solutions across various healthcare sectors, supporting the growth and development of the industry in the UAE and beyond.